Other notable PMBCL signatures include upregulation of CCL22 and downregulation of GNA13 compared with GCB–DLBCL; upregulation of ICOSLG (inducible T cell costimulator ligand), C17orf99, AKT1S1, and KDM4B and downregulation of MPEG1 (macrophage expressed 1), LYN (involved in the B-cell receptor signaling regulation), MAP3K1, and UBA5 compared with ABC–DLBCL; and upregulation of ASB12 and MORC2 and downregulation of IGK@/IGKC compared with unclassifiable DLBCL. The gene discussed is CCL22; the disease is diffuse large B-cell lymphoma.